Endotronix Receives IDE Approval for the Market Expanding PROACTIVE-HF 2 Clinical Trial

The PROACTIVE-HF 2 trial is designed to expand access to NYHA class II patients and to scale pulmonary artery pressure-guided therapy with the Cordella Sensor In addition, the Company presented positive 12-month clinical data on a subset of patients in ... Devices, Interventional, Cardiology, FDA Endotronix, Cordella Sensor, pulmonary artery, pressure-guided therapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news